Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01645787 · ClinicalTrials.gov registry record · Phase 2
Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01645787 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 11 participants.
The verdict
NCT01645787, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether 4-AP (Dalfampridine-ER, Ampyra) improves walking ability and endurance in adult patients with Spinal muscular atrophy (SMA) Type 3 compared to placebo and whether the duration of treatment affects outcome.
Interventions
- DRUG Placebo
- DRUG 4-aminopyridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2012-06-01 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01645787
The ClinicalTrials.gov registry entry for NCT01645787 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01645787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01645787 about?
NCT01645787 is a clinical study titled "Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients". The purpose of this study is to assess whether 4-AP (Dalfampridine-ER, Ampyra) improves walking ability and endurance in adult patients with Spinal muscular atrophy (SMA) Type 3 compared to placebo and whether the duration of treatment affects outcome.
What is the current status of trial NCT01645787?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2012-06-01. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01645787?
The interventions under investigation include: Placebo (DRUG), 4-aminopyridine (DRUG).
Who is sponsoring clinical trial NCT01645787?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.